These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29432493)

  • 1. Mediation analysis for logistic regression with interactions: Application of a surrogate marker in ophthalmology.
    Jensen SM; Hauger H; Ritz C
    PLoS One; 2018; 13(2):e0192857. PubMed ID: 29432493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A measure of the proportion of treatment effect explained by a surrogate marker.
    Wang Y; Taylor JM
    Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation structure of longitudinal measurements of vision in patients with macular degeneration.
    Burzykowski T; Buyse M
    Pharm Stat; 2011; 10(2):115-21. PubMed ID: 20146243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unifying approach for surrogate marker validation based on Prentice's criteria.
    Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
    Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual acuity outcomes among sham vs no-treatment controls from randomized trials.
    Hawkins BS; Bressler NM; Reynolds SM
    Arch Ophthalmol; 2009 Jun; 127(6):725-31. PubMed ID: 19506188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes.
    Molenberghs G; Geys H; Buyse M
    Stat Med; 2001 Oct; 20(20):3023-38. PubMed ID: 11590630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable.
    Ditlevsen S; Christensen U; Lynch J; Damsgaard MT; Keiding N
    Epidemiology; 2005 Jan; 16(1):114-20. PubMed ID: 15613954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inference for Surrogate Endpoint Validation in the Binary Case.
    Bebu I; Mathew T; Agan B
    J Biopharm Stat; 2015; 25(6):1272-84. PubMed ID: 25616958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology.
    Ophthalmology; 2000 Dec; 107(12):2314-7. PubMed ID: 11186878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the effect of the surrogate marker by information gain.
    Qu Y; Case M
    Biometrics; 2007 Sep; 63(3):958-62; author reply 962-3. PubMed ID: 17825025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
    Kobayashi F; Kuroki M
    Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of sham controls in clinical trials.
    Weinberg DV
    Arch Ophthalmol; 2010 May; 128(5):647-8; author reply 648. PubMed ID: 20457994
    [No Abstract]   [Full Text] [Related]  

  • 15. Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    García-Fiñana M; Murjaneh S; Mahmood S; Harding SP
    Eye (Lond); 2010 Jul; 24(7):1213-9. PubMed ID: 20075972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To mask or not to mask.
    Beck RW
    Arch Ophthalmol; 2009 Jun; 127(6):801-2. PubMed ID: 19506202
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973.
    Richer SP; Stiles W; Graham-Hoffman K; Levin M; Ruskin D; Wrobel J; Park DW; Thomas C
    Optometry; 2011 Nov; 82(11):667-680.e6. PubMed ID: 22027699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal antibodies targeting VEGF in ophthalmology: the case of exudative age-related macular degeneration].
    Leveziel N; Soubrane G; Souied EH
    Med Sci (Paris); 2009 Dec; 25(12):1105-7. PubMed ID: 20035686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
    Kumar A; Sahni JN; Stangos AN; Campa C; Harding SP
    Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model.
    Holz FG; Korobelnik JF; Lanzetta P; Mitchell P; Schmidt-Erfurth U; Wolf S; Markabi S; Schmidli H; Weichselberger A
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):405-12. PubMed ID: 19661237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.